Ciftci et al. [43] reported a higher level of the pro-inflammatory and pro-fibrotic cytokine TGF-β1 associated with better survival after two years’ follow-up in metastatic BC patients treated with CHT or combined CHT and RT, although no detailed information regarding the RT schedule for patients was specified. The gene discussed is TGFB1; the disease is breast cancer.